Search
Support us
  • RESEARCH
  • PUBLICATIONS
  • VALIDATION OF CANCER-TYPE-DEPENDENT BENEFIT FROM IMMUNE CHECKPOINT BLOCKADE IN TMB-H TUMORS IDENTIFIED BY THE FOUNDATIONONE CDX ASSAY.

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

  • Show more authors
    + 10
  • D J McGrail
  • P G Pilié
  • N U Rashid
  • L Voorwerk
  • M Slagter
  • M Kok
  • E Jonasch
  • M Khasraw
  • A B Heimberger
  • N T Ueno
  • R Ferrarotto
  • J T Chang
  • S-Y Lin

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology
  • Volume 33
  • Issue nr. 11
  • Pages 1204-1206
  • Publication date 01-11-2022
Full text links

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.